Application Notes

Use of self-interaction parameters derived from light scattering experiments for better developability assessment of biologic therapeutics

Issue link: https://resources.nanotempertech.com/i/1426553

Contents of this Issue

Navigation

Page 3 of 9

©2021 NanoTemper Technologies, Inc. South San Francisco, CA, USA. All Rights Reserved. 4 APPLICATION NOTE Figure 1 shows that candidate molecules 1 and 2 exhibited negative k D for all buffer systems. Histidine-based buffers showed the most success for molecules 3-5. This information allows not only the selection of the ideal molecule to move forward with during development, but also the optimal buffer conditions for storage and assays. These molecules had been previously investigated for their self-interaction behavior using a plate-reading system. As the goal of the EAP project was to ensure that Panta gave accurate measurements that agree with current literature values, the k D values measured on each system were compared. Figure 2 demonstrates that the results obtained from the Panta are in good agreement with those from previous plate reader experiments. mAb1 k D (mL/g) 0.0 -5.0 -10.0 -15.0 -20.0 -25.0 -30.0 Citrate pH 5.5 Panta Plate reader Panta Plate reader His pH 5.5 -2.60 -2.26 -26.31 -25.38 k D (ml/g) Figure 2: Representative comparison of DLS k D values between Prometheus Panta (EAP) and a plate reader system. The values agree within standard deviation; the Panta demonstrated less variation between triplicates. The k D values obtained from Panta DLS quickly and efficiently show which candidates and formulations have optimal self-association values to decrease the potential for aggregation at higher concentrations. The values obtained from the Panta also line up well with previously published data, demonstrating how it can be reliably instituted into existing workflows.

Articles in this issue

view archives of Application Notes - Use of self-interaction parameters derived from light scattering experiments for better developability assessment of biologic therapeutics